Skip to content
OpenCapital
Get started
Biogen logo

Biogen (BIIB) Q1 2024 Earnings

BIIB·Reported April 24, 2024·Before market open

Biogen reported Q1 2024 revenue of $2.2B, missed analyst consensus of $2.3B by $108.8M. Diluted EPS came in at $3.67, beat the $3.47 consensus by $0.20. Biogen reports across 4 business segments, led by Neurology, Rare Disease, and Anti-CD20 Therapeutic Programs.

Revenue
$2.2Bmissed by $108.8M
Consensus: $2.3B
Diluted EPS
$3.67beat by $0.20
Consensus: $3.47
SEC

SEC Filings

Earnings release8-K · 0000875045-24-000012
Quarterly report10-Q · 0000875045-24-000016

Financial Snapshot

Trailing eight quarters through Q1 2024

View all metrics

Q1 2024 Earnings FAQ

Common questions about Biogen's Q1 2024 earnings report.

Biogen (BIIB) reported Q1 2024 earnings on April 24, 2024 before market open.

Biogen reported revenue of $2.2B and diluted EPS of $3.67 for Q1 2024.

Revenue missed the consensus estimate of $2.3B by $108.8M. EPS beat the consensus estimate of $3.47 by $0.20.

You can read the 8-K earnings release (0000875045-24-000012) and the 10-Q periodic report (0000875045-24-000016) directly on SEC EDGAR. The filing index links above go to sec.gov.